TY - JOUR
T1 - Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months
T2 - A randomized controlled trial
AU - Klein, Allan L.
AU - Grimm, Richard A.
AU - Jasper, Susan E.
AU - Murray, R. Daniel
AU - Apperson-Hansen, Carolyn
AU - Lieber, Elizabeth A.
AU - Black, Ian W.
AU - Davidoff, Ravin
AU - Erbel, Raimund
AU - Halperin, Jonathan L.
AU - Orsinelli, David A.
AU - Porter, Thomas R.
AU - Stoddard, Marcus F.
PY - 2006/2
Y1 - 2006/2
N2 - Background: Electrical cardioversion in patients with atrial fibrillation (AF) is associated with an increased risk of stroke. We compared a transesophageal echocardiography (TEE)-guided strategy with a conventional strategy in patients with AF >2 days' duration undergoing electrical cardioversion over a 6-month follow-up. Methods: The ACUTE study was a multicenter, randomized, clinical trial, with 1222 patients. Six-month follow-up was available in 1034 patients (85%), 525 in the TEE group and 509 in the conventional group. The primary composite end points were cerebrovascular accident, transient ischemic attack, and peripheral embolism at 6 months, which was a prespecified time point. Secondary end points were hemorrhage, mortality, and sinus rhythm. Results: At 6 months, there was no difference in composite embolic events between the TEE group and the conventional group (10 [2%] vs 4 [0.8%]; risk ratio (RR) 2.47, 95% CI 0.78-7.88; P = .11). However, the hemorrhagic rate was significantly lower in the TEE group (23 [4.4%] vs 38 [7.5%]; RR 0.58, 96% CI 0.35-0.97; P = .04). There was no difference between the 2 treatment groups in all-cause mortality (21 [4%] vs 14 [2.8%]; RR 1.48, 95% CI 0.76-2.92; P = .25) and in the occurrence of normal sinus rhythm between the 2 groups (305 [62.2%] vs 280 [58.1%]; P = .51). Sinus rhythm at 6 months was more common in the TEE-guided group, in those patients who had direct current cardioversion (238 [62.5%] vs 151 [53.9%]; P = .03). Conclusion: The TEE-guided strategy may be considered a clinically effective alternative to a conventional anticoagulation strategy for patients with AF of >2 days' duration undergoing electrical cardioversion over a 6-month period.
AB - Background: Electrical cardioversion in patients with atrial fibrillation (AF) is associated with an increased risk of stroke. We compared a transesophageal echocardiography (TEE)-guided strategy with a conventional strategy in patients with AF >2 days' duration undergoing electrical cardioversion over a 6-month follow-up. Methods: The ACUTE study was a multicenter, randomized, clinical trial, with 1222 patients. Six-month follow-up was available in 1034 patients (85%), 525 in the TEE group and 509 in the conventional group. The primary composite end points were cerebrovascular accident, transient ischemic attack, and peripheral embolism at 6 months, which was a prespecified time point. Secondary end points were hemorrhage, mortality, and sinus rhythm. Results: At 6 months, there was no difference in composite embolic events between the TEE group and the conventional group (10 [2%] vs 4 [0.8%]; risk ratio (RR) 2.47, 95% CI 0.78-7.88; P = .11). However, the hemorrhagic rate was significantly lower in the TEE group (23 [4.4%] vs 38 [7.5%]; RR 0.58, 96% CI 0.35-0.97; P = .04). There was no difference between the 2 treatment groups in all-cause mortality (21 [4%] vs 14 [2.8%]; RR 1.48, 95% CI 0.76-2.92; P = .25) and in the occurrence of normal sinus rhythm between the 2 groups (305 [62.2%] vs 280 [58.1%]; P = .51). Sinus rhythm at 6 months was more common in the TEE-guided group, in those patients who had direct current cardioversion (238 [62.5%] vs 151 [53.9%]; P = .03). Conclusion: The TEE-guided strategy may be considered a clinically effective alternative to a conventional anticoagulation strategy for patients with AF of >2 days' duration undergoing electrical cardioversion over a 6-month period.
UR - http://www.scopus.com/inward/record.url?scp=31444443926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=31444443926&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2005.07.011
DO - 10.1016/j.ahj.2005.07.011
M3 - Article
C2 - 16442904
AN - SCOPUS:31444443926
SN - 0002-8703
VL - 151
SP - 380
EP - 389
JO - American Heart Journal
JF - American Heart Journal
IS - 2
ER -